Mudaliar, S., Armstrong, D. A., Mavian, A. A., O’Connor-Semmes, R., Mydlow, P. K., Ye, J., … Dobbins, R. L. (2012). Remogliflozin Etabonate, a Selective Inhibitor of the Sodium-Glucose Transporter 2, Improves Serum Glucose Profiles in Type 1 Diabetes. Diabetes Care, 35(11), 2198–2200. https://doi.org/10.2337/dc12-0508

Mudaliar, Sunder, Debra A. Armstrong, Annie A. Mavian, Robin O’Connor-Semmes, Patricia K. Mydlow, June Ye, Elizabeth K. Hussey, Derek J. Nunez, Robert R. Henry, and Robert L. Dobbins. “Remogliflozin Etabonate, a Selective Inhibitor of the Sodium-Glucose Transporter 2, Improves Serum Glucose Profiles in Type 1 Diabetes.” Diabetes Care 35, no. 11 (November 1, 2012): 2198–2200. https://doi.org/10.2337/dc12-0508.

Mudaliar S, Armstrong DA, Mavian AA, O’Connor-Semmes R, Mydlow PK, Ye J, et al. Remogliflozin Etabonate, a Selective Inhibitor of the Sodium-Glucose Transporter 2, Improves Serum Glucose Profiles in Type 1 Diabetes. Diabetes Care. 2012 Nov 1;35(11):2198–200.

Mudaliar, Sunder, et al. “Remogliflozin Etabonate, a Selective Inhibitor of the Sodium-Glucose Transporter 2, Improves Serum Glucose Profiles in Type 1 Diabetes.” Diabetes Care, vol. 35, no. 11, American Diabetes Association, Nov. 2012, pp. 2198–200. Crossref, doi:10.2337/dc12-0508.

Mudaliar S, Armstrong DA, Mavian AA, O’Connor-Semmes R, Mydlow PK, Ye J, Hussey EK, Nunez DJ, Henry RR, Dobbins RL. Remogliflozin Etabonate, a Selective Inhibitor of the Sodium-Glucose Transporter 2, Improves Serum Glucose Profiles in Type 1 Diabetes. Diabetes Care. American Diabetes Association; 2012 Nov 1;35(11):2198–2200.